Ischemic stroke and hyperhomocysteinemia: Truth or myth?

Acta Neurologica Belgica

Volumn 109, Issue 3, 2009, Pages 181-188

  Terwecoren, Annelies ^a   Steen, E ^b   Benoit, D ^b   Boon, P ^a   Hemelsoet, D ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Hyperhomocysteinemia; Ischemic stroke; Methionine homocysteine metabolism; Secondary prevention; Vitamin therapy

Indexed keywords

ACETYLSALICYLIC ACID; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LOW MOLECULAR WEIGHT HEPARIN; METHIONINE; PYRIDOXINE;

AMINO ACID METABOLISM; ANAMNESIS; ARTERY THROMBOSIS; BLOOD CLOT LYSIS; BLOOD EXAMINATION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; DRUG EFFECT; ECHOCARDIOGRAPHY; FOLLOW UP; GENETIC POLYMORPHISM; HEALTH CARE ORGANIZATION; HUMAN; HYPERHOMOCYSTEINEMIA; MEDICAL PRACTICE; MEDICAL SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; TREATMENT OUTCOME; VASCULAR DISEASE; VITAMIN DEFICIENCY;

ADULT; BRAIN ISCHEMIA; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); RISK FACTORS; STROKE; VITAMINS;

EID: 70449095217     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Albert CM, Cook NR, Gaziano JM, Zaharris E, Mac Fadyen J. et al. Effect of Folic Acid and B Vitamins on Risk of Cardiovascular Events and Total Mortality Among Women at High Risk for Cardiovascular Disease. JAMA. 2008;299:2027-2036.
2. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M. et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19. (Pubitemid 24103795)
3. Bazzano L, Reynolds K, Holder K, He J. Effect of folic acid supplementation on risk of cardiovascular diseases. A meta-analysis of randomized controlled trials. JAMA. 2006;296:2720-2726.
4. Boers GH, Smals AG, Trijbels FJ, Fowler B, Bakkeren JA. et al. Heterozygosity for homocystinuria in premature perifheral and cerebral occlusive arterial disease. N Engl J Med. 1985;313:709-715.
5. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A. et al. Homocysteine Lowering and cardiovascular Events after Acute Myocardial Infarction. N Engl J Med. 2006;354:1578-1588.
6. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A. et al. Homocysteine and Short-term Risk of Myocardial Infarction and Stroke in the Elderly. The Rotterdam Study. Arch Intern Med. 1999;159:38-44.
7. Casas JP, Bautista LE, Smeeth L Sharma P, Hingorani A. Homocysteine and stroke: evidence on a causal link from medelian randomisation. Lancet. 2005;365: 224-232. (Pubitemid 40138016)
8. Ebbing M, Oyvind B, Ueland PM, Nordrehaug JE, Nilsen DW. et al. Mortality and Cardiovascular Events in Patients Treated With Homocysteine- Lowering B Vitamins After Coronary Angiography. JAMA 2008;300:795-804.
9. European Concerted Action Project. Plasma homocysteine as a risk factor for vascular disease. JAMA. 1997;277:1775-1781.
10. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25:457-507.
11. Faraci FM, Lentz SR. Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke. 2004;35:345-347. (Pubitemid 38174401)
12. Hankey GJ. Is plasma homocysteine a modifiable risk factor for stroke? Nat Clin Pract Neurol. 2006;2:26-33
13. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1667-1677
14. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. A meta- analysis. JAMA. 2002;288:2016-2022.
15. Kaul S, Zadeh AA, Shah PK. Homocysteine hypothesis for atherothrombotic cardiovascular disease. J Am Coll Cardiol. 2006;48:915-923
16. Laloux P. Cost of acute stroke. A review. Acta Neurol belg. 2003;103:71-77.
17. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM. et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle- aged British men. Lancet. 1995;346:1395-1398.
18. Pezzini A, Grassi M, Del Zotto E, Assanelli D, Archetti S. et al. Interaction of homocysteine and conventional predisposing factors on risk of ischaemic stroke in young people: consistency in phenotype-diseaese analysis and genotype-disease analysis. J Neurol Neurosurg Psychiatry. 2006;77:1260-1266. (Pubitemid 44453249)
19. Sacco R, Adams R, Albers G, Alberts M, Benavente O. et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke. 2006; 37:577-617
20. Search Study Collaborative Group Oxford, UK. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): Characteristics of a randomized trial among 12064 myocardial infarction survivors. Am Heart J. 2007;154:815-823.
21. Spence JD, Bang H, Chambless LE, Stampfer MJ. et al. Vitamin Intervention for stroke prevention trial. An efficacy analysis. Stroke. 2005;36:2404-2409.
22. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol. 2007;6:830-838.
23. Spence JD. Perspective on the efficacy analysis of the Vitamin Intervention for Stroke Prevention Trial. Clin Chem Lab Med. 2007;45:1582-1585.
24. Toole JF, Malinow MR Chambless LE Spence JD, Pettigrew LC. et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the vitamin intervention for stroke prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-575.
25. Vanbrabant P, Van Den Bosch G, Gheuens E, Baeck E, Nutten D. et al. Cerebrovasculair accident en hyperhomocysteïnemie. Tijdschr voor Geneeskunde. 2001;57:463-468.
26. VITATOPS (Vitamins to Prevent Stroke) TRIAL. Rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis. 2002;13;120-126.
27. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1302-1306. (Pubitemid 35398783)
28. Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ. 2006;333:1215-1217.
29. Welch NG, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-1050
30. Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence. Diabetes Vasc Dis Res. 2007;4:143-149. (Pubitemid 47178770)